Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Peter Voorhees named associate director of clinical research at Wake Forest

Peter Voorhees was promoted to associate director of clinical research and will oversee clinical research for Atrium Health Wake Forest Baptist Comprehensive Cancer Center, as well as all processes related to clinical protocol and data management and protocol review and monitoring system.

June 20, 2025

Vol.51 No.24

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology.

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.

May 30, 2025

Vol.51 No.21

In Brief

KU Cancer Center breaks ground for new complex

The University of Kansas Cancer Center broke ground on the future site of a new complex on May 22 that will bring research and patient care into one area for the first time in KU Cancer Center’s history.

May 30, 2025

Vol.51 No.21

In Brief

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Intermountain Health is now offering a national expansion of CAR-T cell therapy, bringing cancer care closer to patients in southern Utah and Nevada.

May 16, 2025

Vol.51 No.19

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

YOU MAY BE INTERESTED IN

Peter Voorhees named associate director of clinical research at Wake Forest

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

KU Cancer Center breaks ground for new complex

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Renew today!

Subscriber content

Never miss an issue!

Login

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

YOU MAY BE INTERESTED IN

Peter Voorhees named associate director of clinical research at Wake Forest

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher findsCells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

KU Cancer Center breaks ground for new complex

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Never miss an issue!

Login

Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response